Linked Data API

Show Search Form

Search Results

686153
registered interest false more like this
date less than 2017-02-07more like thismore than 2017-02-07
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Brentuximab Vedotin more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, what steps his Department is taking to ensure relapsed and refractory Hodgkin lymphoma patients continue to have access to brentuximab vedotin. more like this
tabling member constituency Crawley more like this
tabling member printed
Henry Smith remove filter
uin 63498 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2017-02-15more like thismore than 2017-02-15
answer text <p>Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) provides independent, evidence-based guidance for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE is appraising Brentuximab for this indication and recently consulted stakeholders on its draft recommendations. Brentuximab is currently available to NHS patients with relapsed and refractory Hodgkin lymphoma through the Cancer Drugs Fund.</p> more like this
answering member constituency Oxford West and Abingdon more like this
answering member printed Nicola Blackwood more like this
question first answered
less than 2017-02-15T13:39:18.99Zmore like thismore than 2017-02-15T13:39:18.99Z
answering member
4019
label Biography information for Baroness Blackwood of North Oxford more like this
tabling member
3960
label Biography information for Henry Smith more like this